Potent inhibitor of protein phosphatase types 2A (PP2A) and 4 (PP4) with IC50
values of 1.5 nM and 3 nM respectively. Also exhibits weaker inhibition of topoisomerase II (IC50
= 40 μ
M) and protein phosphatase type 1 (PP1) (IC50
= 131 μ
M) with no apparent inhibition of protein phosphatase type 2B (PP2B). Active in vivo
. Originally identified as an antitumor antibiotic from Streptomyces pulveraceous
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Novel antitumor agents CI-920, PD 113,270 and PD 113,271. I. Taxonomy, fermentation and biological properties.
Tunac et al.
Fostriecin, an antitumor antibiotic with inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) and 2A (PP2A), is highly selective for PP2A.
Walsh et al.
FEBS Lett., 1997;416:230
Purification of protein phosphatase 4 catalytic subunit: inhibition by the antitumour drug fostriecin and other tumour suppressors and promoters.
Hastie and Cohen
FEBS Lett., 1998;431:357
The citations listed below are publications that use Tocris products. Selected citations for Fostriecin sodium salt include:
Showing Results 1 - 4 of 4